This is a preprint.
Leucine Aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
- PMID: 39713462
- PMCID: PMC11661280
- DOI: 10.1101/2024.12.13.628212
Leucine Aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Update in
-
Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins.Science. 2025 Mar 28;387(6741):eadq8331. doi: 10.1126/science.adq8331. Epub 2025 Mar 28. Science. 2025. PMID: 40146846
Abstract
Proteolysis of hydrophobic helices is required for complete breakdown of every transmembrane protein trafficked to the lysosome and sustains high rates of endocytosis. However, the lysosomal mechanisms for degrading hydrophobic domains remain unknown. Combining lysosomal proteomics with functional genomic data mining, we identify Lysosomal Leucine Aminopeptidase (LyLAP; formerly Phospholipase B Domain-Containing 1) as the hydrolase most tightly associated with elevated endocytic activity. Untargeted metabolomics and biochemical reconstitution demonstrate that LyLAP is not a phospholipase, but a processive monoaminopeptidase with strong preference for N-terminal leucine - an activity necessary and sufficient for breakdown of hydrophobic transmembrane domains. LyLAP is upregulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake, and its ablation led to buildup of undigested hydrophobic peptides, which compromised lysosomal membrane integrity and inhibited PDA cell growth. Thus, LyLAP enables lysosomal degradation of membrane proteins, and may represent a vulnerability in highly endocytic cancer cells.
One sentence summary: LyLAP degrades transmembrane proteins to sustain high endocytosis and lysosomal membrane stability in pancreatic cancer.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources